Three Lakes Foundation and the American College of Chest Physicians (CHEST) recently announced their collaboration on a multiphase educational initiative aiming to reduce the time it takes to diagnose patients with Interstitial Lung Diseases (ILD).
Two strategic biopharmaceutical collaborations were announced, each merging one company’s innovative biologic technology with a second company that can drive potential therapeutics over the finish line to commercialization.
Money on the Move: January 19 – 25Algorithms, Appointments, Biotech, Business, Cell Therapy, Cells, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Coronavirus, CRISPR, Drug Discovery, Fibrosis, Financing, Gene Editing, Inflammatory Bowel Disease (IBD), Influenza, Mammalian, Moderna, Monoclonal Antibodies, Nasal drug delivery, Oncology, People on the Move, Product Pipelines, R&D, RNA, Series A, Series B
Temps are falling and so is investor cash as BioSpace reviewed which biotech companies are scooping up the dollars.
NGM Biopharmaceuticals’ aldafermin failed to hit the primary endpoint in the company’s Phase IIb ALPINE 2/3 trial for non-alcoholic steatohepatitis (NASH) with stage 2 or 3 liver fibrosis.
Stephen Byers, Ph.D., associate director and professor of oncology at Georgetown Lombardi, and his team published a paper in the journal Gastroenterology regarding their findings of a novel target for pancreatic cancer therapy.
Inventiva, with headquarters in Daix, France, received Breakthrough Therapy designation from the U.S. Food and Drug Administration for the company’s lanifibranor for nonalcoholic steatohepatitis (NASH).
Topline results from a 28-week Phase IIb trial show that lenabasum, a novel oral small molecule developed by Massachusetts-based Corbus Pharmaceuticals, did not reduce the rate of new pulmonary exacerbations compared with placebo in patients with cystic fibrosis (CF).
Two years after nabbing three novel anti-infective drug candidates from Novartis for the treatment of antibiotic-resistant infections, Boston Pharmaceuticals struck a deal with the Swiss pharma giant for a potential treatment for non-alcoholic steatohepatitis (NASH).
Following negative interim data from the company’s experimental treatment for non-alcoholic steatohepatitis (NASH) and fibrosis, France’s GENFIT will discontinue the Phase III RESOLVE-IT study of elafibranor in this indication.
Lassen Therapeutics, based in San Diego, came out of stealth mode with a $31 million Series A financing round.